Silvan Tuerkcan, an analyst from JMP Securities, maintained the Buy rating on Cellectis SA (CLLS – Research Report). The associated price target is $6.00.
Silvan Tuerkcan’s rating is based on Cellectis SA’s significant advancements in its clinical programs and strategic collaborations. The company has undergone a pipeline overhaul and received strategic investment from AstraZeneca, which has bolstered its financial position with a substantial cash balance to support operations into mid-2027. This financial stability, coupled with anticipated clinical updates in the second half of 2025, underpins the positive outlook.
Key developments include the progression of the UCART22 program, with late-stage data expected in the third quarter of 2025, and the expansion of clinical trial sites in the EU, UK, and U.S. Furthermore, the collaboration with AstraZeneca is progressing well, focusing on innovative projects in hematological malignancies, solid tumors, and gene therapy. This collaboration has already resulted in significant milestone payments, enhancing Cellectis’s growth prospects. Overall, these factors contribute to the Buy rating, reflecting confidence in the company’s strategic direction and potential for value creation.
In another report released today, Barclays also maintained a Buy rating on the stock with a $5.00 price target.